^
Association details:
| Biomarker: | IFNG 4-genes signature |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small-Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Excerpt:
In the NSCLC discovery set, a four-gene interferon gamma (IFNγ)–positive (IFNγ+ ) signature comprising IFNγ, CD274, LAG3, and CXCL9 was associated with higher overall response rates, longer median progression-free survival, and overall survival compared with signature-low patients....The IFNγ+ mRNA signature may assist in identifying patients with improved outcomes to durvalumab, independent of PD-L1 assessed by IHC...Table 4. ORR, OS, and PFS by IFNγ mRNA signature or PD-L1 status in UC patients.
DOI:
10.1158/1078-0432.CCR-17-3451